Selling Cosmetics in Canada: The Health Canada Compliance Gaps Most European Brands Don't See Coming

Most European cosmetics brands that decide to expand into North America fix their attention on the US market — and understandably so. The FDA’s post-MoCRA requirements are significant and well-publicised. Canada, by contrast, tends to get treated as a gentler afterthought: a market you’ll sort out once you’ve navigated the US. That assumption costs brands time and money in ways that are entirely avoidable.

Canada has its own regulatory logic for cosmetics, governed by the Canada Consumer Product Safety Act (CCPSA, S.C. 2010, c. 21) and the Cosmetic Regulations (CRC, c. 869). These are not FDA frameworks and they are not EU Regulation 1223/2009. The three systems share some principles — post-market accountability, prohibited substance lists, labelling requirements — but they diverge at precisely the points where European brands are most confident they’ve already covered the ground.

Canada Is Not a Softer FDA — It Has Its Own Regulatory Framework

The first misconception worth clearing up: because Canada and the US are close trade partners, and because Health Canada occasionally references FDA standards in its guidance documents, European companies assume the markets are substantially similar. For cosmetics, they aren’t.

Under the CCPSA, cosmetics must be notified to Health Canada within 10 days of the first sale in Canada. This is a post-market notification — which feels familiar to European brands accustomed to the CPNP (Cosmetic Products Notification Portal). But the Canadian notification is submitted through the Cosmetic Notification Form (CNF), requires different data fields than CPNP, and — critically — requires a Canadian-based responsible person to be identified directly on the product label. That responsible person must have a Canadian postal address. Your French or German headquarters doesn’t qualify.

That label requirement alone delays a surprising number of launches. Your EU label, compliant in 27 member states, isn’t compliant in Canada. You need a Canadian contact — an importer, distributor, or regulatory agent — whose address appears on the packaging. And Canada’s Consumer Packaging and Labelling Act requires that labelling appear in both official languages. For a Paris-based brand, the French copy is done. But the English version must meet Canadian regulatory phrasing standards, not simply a direct translation of your EU label claims.

The NHP vs. Cosmetic Classification — Canada’s Costliest Trap for European Brands

This is where European brands most consistently underestimate the Canadian market. In the EU, the boundary between a cosmetic and a medicinal product rests primarily on the product’s intended function: does it restore, correct, or modify physiological functions? Canada uses a similar principle in theory, but Health Canada draws the cosmetic/NHP boundary partly on the basis of ingredient identity and concentration — not just claims.

Products containing botanical extracts, vitamins at therapeutic-range concentrations, certain minerals, or probiotics may be classified as Natural Health Products (NHPs) under the Natural Health Products Regulations (SOR/2003-196) — requiring a Natural Product Number (NPN) before they can legally be sold in Canada. No NPN means no lawful sale, regardless of how smoothly the product passed your EU borderline product assessment.

NPN licensing timelines are not trivial. Class I applications (simpler, often homeopathic formulations) are typically processed within 60 days. Class II applications — which cover most botanical-forward or vitamin-complex cosmetics — routinely take 6 to 18 months. Class III, for more complex products, can run considerably longer. The scenario we work through repeatedly with European clients: a premium serum containing a high-concentration vitamin C complex or a multi-botanical active, perfectly classified and sold as a cosmetic across the EU, enters Canada without a prior classification analysis. Health Canada issues a compliance notice six months post-launch. The brand halts distribution until licensing is complete. An entire Canada season is lost.

The fix is straightforward — but it has to happen before you commission Canadian packaging. A formal classification review against Health Canada’s published guidance on the cosmetic-NHP boundary is not optional; it’s the first step in any serious Canada market entry plan.

Health Canada’s Cosmetic Hotlist: Where Your EU Safety Assessment Falls Short

European cosmetics brands arrive in Canada with a rigorous dossier. A full toxicological evaluation under Annex I of Regulation 1223/2009. Prohibited substance screening against Annexes II and III. Often a REACH compliance package for the supply chain. It represents a genuine body of scientific work — and it still leaves real gaps in the Canadian context.

Health Canada maintains the Cosmetic Ingredient Hotlist, an independently developed and regularly updated registry of restricted and prohibited ingredients. As of the most recent revision, the Hotlist contains approximately 500 ingredient entries — covering outright prohibitions, restricted-use substances, and permitted colorants with specific conditions of use. The Hotlist and the EU’s Annex II/III lists were developed by different scientific bodies under different policy mandates. They are not mirrors of each other.

A few concrete divergences worth noting:

• Certain synthetic dyes and colorants permitted in EU leave-on products appear on the Canadian Hotlist as prohibited or restricted under different conditions.
• Triclosan is addressed under both frameworks but with distinct concentration limits and category restrictions that don’t fully align.
• Benzophenone UV filters have been revised under both systems in recent years — not always in parallel, and not always to the same endpoints.
• Formaldehyde-releasing preservatives carry Hotlist limits that differ from the EU Annex V thresholds your safety assessor calibrated against.

A cosmetic safety assessment that fully satisfies EU Regulation 1223/2009 cannot be submitted as-is to demonstrate Canadian compliance. Hotlist screening is a separate step — typically faster than a full safety review, but it must be done against the current version of the Hotlist, not a version from 18 months ago. Health Canada updates the list, and the updates matter.

What Market Entry Actually Looks Like: A Practical Compliance Checklist

Based on what we work through with European brands entering Canada, here is the sequence that avoids the expensive redirects:

Step 1 — Conduct a classification analysis. Before anything else, determine whether each SKU is a cosmetic or an NHP under Canadian regulations. This is especially critical for products containing vitamins at meaningful doses, botanical actives, probiotics, or minerals. This analysis is not the same as your EU borderline product assessment.

Step 2 — Screen against the current Cosmetic Ingredient Hotlist. Run every formulation against the most recently published version of the Hotlist. Flag restricted ingredients and confirm that your concentrations and use conditions fall within permitted ranges. Don’t use a cached copy — fetch the current version directly from Health Canada’s website.

Step 3 — Conduct a Canada-specific label compliance review. Your Canadian label requires: the name and Canadian address of a responsible person, bilingual copy in English and French conforming to Canadian regulatory phrasing, an ingredient declaration in INCI nomenclature as required under the Cosmetic Regulations, and net quantity in metric units. Review all claims for language that might push the product toward NHP classification.

Step 4 — Appoint a Canadian responsible person. This can be an importer, a distributor operating under a formal regulatory agreement, or a dedicated regulatory agent based in Canada. This party is legally accountable for the cosmetic notification submission and for maintaining the product record under Canadian law.

Step 5 — Submit the Cosmetic Notification Form within 10 days of first sale. The CNF is submitted electronically through Health Canada’s online portal. It requires the product name, responsible person details, intended use, a complete ingredient list, and a designated contact for adverse reaction reporting. Retain your submission confirmation — it is your primary evidence of compliance.

Step 6 — Establish a Canadian adverse reaction reporting procedure. Health Canada requires serious adverse reactions to be reported within 10 days of the responsible person becoming aware of the event. This is operationally distinct from your EU cosmetovigilance process and requires a Canadian-law-compliant intake and documentation procedure.

For brands managing EU, US, and Canadian compliance simultaneously, the most effective approach we’ve seen is building a master formulation dossier and generating market-specific output documents from it — rather than treating each market as a separate project from scratch. It requires upfront structure, but it prevents the exponential documentation burden as you scale across markets.

The Business Case for Getting This Right Before Launch

Canada’s cosmetics and personal care market reached approximately CAD $4.2 billion in retail sales in 2024, with natural, premium, and European-provenance brands among the fastest-growing segments. French cosmetics brands in particular carry a meaningful provenance premium in Canadian retail. The demand is real and growing.

But Canada is not a market you enter on a wing and a regulatory assumption. The compliance framework is distinct, the NHP classification risk is genuine for a large proportion of contemporary European formulations, and the notification timeline is short. Brands that enter Canada smoothly are almost always those that engaged Canadian-specific regulatory support at the formulation review stage — not after the packaging artwork was already approved.

If your pipeline includes botanical complexes, vitamin-forward actives, or any ingredient with meaningful overlap into the NHP space, the classification question should be the first item on your Canada launch checklist.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry and Canadian compliance strategy. Contact us

Related from our network

• NHP Testing and Health Canada Product Licensing Support — Androxa provides Canadian-based NHP and cosmetic testing services, including formulation screening against the Cosmetic Ingredient Hotlist and classification support for brands entering the Canadian market.
• ISO 17025-Accredited Cosmetic and Supplement Testing for US Market Entry — Qalitex Laboratories offers FDA-aligned cosmetic and supplement testing for European brands preparing for the US market alongside Canadian expansion.